Filana Therapeutics, Inc. Common Stock

FLNANASDAQUSD
0.95 USD
0.02 (2.02%)AT CLOSE (11:59 AM EDT)
0.94
0.01 (1.14%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
0.94
0.01 (1.14%)
🟢Market: OPEN

Shares of Filana Therapeutics, Inc. Common Stock (FLNA) are trading at $0.94. The technical outlook is "Sell" based on moving average alignment, RSI, and MACD signals. Key drivers include negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, FLNA appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Aug 25, 2026.

Open?$0.92
High?$0.96
Low?$0.91
Prev. Close?$0.93
Volume?110.1K
Avg. Volume?318.0K
VWAP?$0.94
Rel. Volume?0.35x
Bid / Ask
Bid?$0.78 × 100
Ask?$0.98 × 700
Spread?$0.19
Midpoint?$0.88
Valuation & Ratios
Market Cap?44.9M
Shares Out?48.3M
Float?45.6M
Float %?94.4%
P/E Ratio?N/A
P/B Ratio?0.71
EPS?-$0.88
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Employees
20
Market Cap
44.9M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2000-07-14
Address
6801 N CAPITAL OF TEXAS HIGHWAY
AUSTIN, TX 78731
Phone: 512-501-2444
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental Outlook
Loading...
Short InterestVery High
Short % of Float?13.84%High
Short Interest?6.3M
Days to Cover?18.6
Free Float45.6M
Avg Daily Volume339.9K
Settlement Date2026-08-14
Financial Health
Current Ratio?2.08Strong
Quick Ratio?2.08Strong
Cash Ratio?2.06Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.71CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
Peers
100
S&P
97
0.8CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-66.5%WEAK
ROA?
S&P
3
-40.7%WEAK
Cash Flow & Enterprise
FCF?$-29304000
Enterprise Value?$-37754657
Fundamentals ratios updated end of day